AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 159 filers reported holding AKERO THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.15 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $5,369,350 | +40.7% | 115,000 | -71.5% | 0.30% | +4.2% |
| Q2 2022 | $3,816,000 | -33.4% | 403,787 | 0.0% | 0.29% | -34.3% |
| Q1 2022 | $5,730,000 | -32.9% | 403,787 | 0.0% | 0.44% | -13.4% |
| Q4 2021 | $8,540,000 | -36.3% | 403,787 | -32.7% | 0.51% | -6.8% |
| Q3 2021 | $13,410,000 | -9.9% | 600,000 | 0.0% | 0.54% | +7.7% |
| Q2 2021 | $14,886,000 | -30.9% | 600,000 | -19.2% | 0.51% | +5.4% |
| Q1 2021 | $21,541,000 | +12.4% | 742,549 | 0.0% | 0.48% | +5.3% |
| Q4 2020 | $19,158,000 | -27.6% | 742,549 | -13.6% | 0.46% | -55.2% |
| Q3 2020 | $26,466,000 | +79.2% | 859,550 | +45.1% | 1.02% | +80.8% |
| Q2 2020 | $14,766,000 | +8.4% | 592,539 | -7.8% | 0.56% | -11.1% |
| Q1 2020 | $13,622,000 | -17.1% | 642,539 | -13.2% | 0.63% | -3.5% |
| Q4 2019 | $16,438,000 | -2.4% | 740,621 | 0.0% | 0.66% | -36.1% |
| Q3 2019 | $16,849,000 | +14.6% | 740,621 | -3.5% | 1.03% | +21.4% |
| Q2 2019 | $14,704,000 | – | 767,842 | – | 0.84% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |